Clinical Trial Update: BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating pembrolizumab added to azacitidine and venetoclax as frontline therapy for unfit acute myeloid leukemia patients; results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Acute Myeloid Leukemia Post Cytotoxic Therapy

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pembrolizumab (pembrolizumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-13